- Case details
- Status—ActionProcedural applicationCategoryCase management orders
- Parties
- Claimants
- Arbutus Biopharma CorporationOperating co.
- Genevant Sciences GmbHNPE
Representatives- Markus van Gardingen
Respondents- Moderna, Inc.Operating co.
- ModernaTX, Inc.Operating co.
- Moderna Belgium S.R.L.Operating co.
- Moderna Italy S.R.L.Operating co.
- Moderna France SASUOperating co.
- Moderna Biotech UK LimitedOperating co.
- Moderna Switzerland GmbHOperating co.
- Moderna Poland Sp. z o.o.Operating co.
- Moderna Portugal Unipessoal LDAOperating co.
- Moderna Sweden ABOperating co.
- Moderna Netherlands B.V.Operating co.
- Moderna Biotech Spain SLOperating co.
- Moderna Denmark ApSOperating co.
- Moderna Germany GmbHOperating co.
- Moderna Norway ASOperating co.
Representatives- Ruben Laddé
- Joachim Renken
- Division
- The Hague LD
- Judges
- —
- Technology
- ChemistryPharmaceuticals · Biotechnology
- Language
- —
- First decided
- Jun 12, 2025
- EPO Opposition
- Merck Sharp & Dohme CorporationAdmissible2018-04-05
- Moderna Therapeutics, Inc.Admissible2018-04-05
- Merck Sharp & Dohme LLCWithdrawn2018-04-05
- ModernaTX, Inc.Withdrawn2018-04-05
- ModernaTX, Inc.Withdrawn2025-04-29
- Merck Sharp & Dohme (UK) LimitedWithdrawn2025-07-23
- Arrowhouse GmbHAdmissible2025-07-23
- Keltie LLPAdmissible2025-07-23
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| The Hague LD | Locked |
At the UPC: Arbutus Biopharma Corporation (12 cases)·Moderna Group (20 cases)
This dispute contains 6 other proceedings
UPC CFI 617/2025·UPC CFI 607/2025·UPC CFI 191/2025·UPC CFI 192/2025·UPC APP 18039/2025 and 1 more
2 other defendants litigating the same or a related patent
Start a free trial to see how each one ended.
More cases: The Hague LD·2025
- 2025-06-12Application RoP 333Public
Summary: The Hague Local Division issued a procedural order on a R. 333 RoP application by various Moderna entities (defendants) regarding service and deadlines for filing the Statement of Defence in infringement proceedings brought by Arbutus Biopharma and Genevant Sciences. The court denied requests to stay service or extend deadlines for individual defendants not yet formally served, while setting a single consolidated deadline for all Moderna group defendants to file one joint Statement of Defence.
Show the legal issues (4)
- Service of process on multiple defendants (R. 333 RoP)
- Streamlining deadlines for corporate group defendants
- Consolidated Statement of Defence by group defendants
- Expeditious proceedings in pharmaceutical patent infringement
- 67F1D71B9121801523F195BB2BA1D2DE_en.pdf2025-06-12EN